Hafron on IsoPSA: A Simpler, Smarter Tool for Prostate Cancer Risk
Jason M. Hafron, MD, discusses IsoPSA, a novel prostate-specific antigen assay for patients with a PSA > 4ng/ml who are facing a decision on prostate biopsy.
Jason M. Hafron, MD, Hafron, chief medical officer and medical director of clinical research at the Michigan Institute of Urology, PC, as well as a professor of urology at the William Beaumont School of Medicine at Oakland University, discusses IsoPSA, a novel prostate-specific antigen assay for patients with a PSA > 4ng/ml who are facing a decision on prostate biopsy, and its role in prostate cancer.
IsoPSA is a blood test for the assessment of men with elevated total PSA ≥ 4ng/mL that helps to identify structural differences in PSA proteins that are expressed by cancer.
“The beauty of IsoPSA is its simplicity, making it very easy to use in the clinic on a day-to-day basis,” explains Hafron.
He also explains that the results of IsoPSA presented at the 2025 AUA Meeting are very straightforward.
“If the IsoPSA is less than 6, we can watch the patient. Based on the recent Abdallah data, if their IsoPSA is low, their risk of clinically significant prostate cancer over the next 30 months is about 5%. Clinically, this will allow me to adjust my discussion with the patient because I am quite confident that a low or negative IsoPSA makes it unlikely that the patient has clinically significant prostate cancer,” says Hafron.
In addition, Hafron explains that the IsoPSA will also affect how he monitors patients. For instance, if a patient has a low IsoPSA, he states that he will not need to see them as frequently, check their PSA as often, or be as thoroughly intensive with monitoring.
He continues, “if a patient has a high IsoPSA, as we have seen in the Abdallah data, they are at risk for clinically significant prostate cancer – about 35%. These patients need to be followed closely, and their treatment needs to be tailored accordingly.”
